<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors investigated the roles of endothelin (ET)-1 and the <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptor in the pathogenesis of delayed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="1" pm="."><plain>A study was made of the preventive effect of a novel <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, BQ-123, on vasospasm and the expression of the <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptor messenger <z:chebi fb="3" ids="33697">ribonucleic acid</z:chebi> (<z:chebi fb="2" ids="33699">mRNA</z:chebi>) using a canine two-<z:mp ids='MP_0001914'>hemorrhage</z:mp> SAH model </plain></SENT>
<SENT sid="2" pm="."><plain>Continuous intrathecal administration of BQ-123 (5 x 10(-6) mol/day) prevented narrowing of the basilar artery on Day 7 after SAH in 97.6% of cases in the study group versus 70.7% of cases in the control group (p &lt; 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>While expression of the <z:chebi fb="2" ids="33699">mRNA</z:chebi>-coding <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptor was not detected in the control animals, it markedly increased on Day 3 after SAH and was also detected on Day 7 </plain></SENT>
<SENT sid="4" pm="."><plain>The results suggest that endothelin-1 and the <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptor participate in the pathogenesis of delayed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following SAH </plain></SENT>
</text></document>